1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. SENORES PHARMACEUTICALS LTD.
Senores Pharmaceuticals Ltd.
NSE: SENORES | BSE: 544319
US FDA InspectionsANDA Approvals
Ask AI about Senores Pharmaceuticals
1090.80-22.10(-1.99%)
250.3K
NSE+BSE Volume

NSE 20 Nov, 2026 3:31 PM

Portfolio

Alert

My Notes

Senores Pharmaceuticals quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Senores Pharmaceuticals share price target, revenues, EPS, net income and more

Senores Pharmaceuticals quarterly results: revenue, profit, and P&L – 13 quarter history

  • POSITIVE

    Quarterly Revenue Senores Pharmaceuticals Sep-2026 Quarterly Revenue is Rs 50 Cr which is growth of 8.0% YoY.

  • POSITIVE

    Quarterly Net Profit Senores Pharmaceuticals Sep-2026 Quarterly Net Profit is Rs 8 Cr which is growth of 20.1% YoY.

Senores Pharmaceuticals Ltd., Quarterly, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23
⌄
50.436.55938.546.728.221.116.812.79.940.911.1
Operating Exp.
34.629.340.329.733.82114.612118.334.19.4
Operating Profit
1.1-2.3-3.5-0.91.5-1.2-2.7-2.4-1.3-0.8-0.1-0.5
Operating Profit Margin %
2.97%-8.63%-9.45%-3.23%4.30%-5.80%-23.10%-25.23%-13.91%-10.29%-0.18%-5.95%
Depr.
3.93.64.13.63.71.91.30.80.50.520.5
Interest
2.22.21.91.81.61.82.42.70.70.82.70.7
Profit Before Tax
9.71.412.73.57.73.62.91.30.50.420.5
Tax
20.44.20.91.20.90.90.30.20.11.20.3
Net Profit
7.718.52.76.42.721.10.30.30.80.2
EPS Adj. latest
1.70.21.80.61.40.60.40.20.10.10.20
Net profit TTM
19.918.620.313.812.26.13.72.51.6---
Basic EPS TTM
4.344.432.71.30.80.50.5---
Earnings Transcripts
    
AI Summary
    
    
Results PDF
    
Result Notes
      
*All financials are in INR Cr and price data in INR

Senores Pharmaceuticals competitor comparison and performance snapshot within industry

Senores Pharmaceuticals annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

  • POSITIVE

    Annual Revenue Senores Pharmaceuticals Mar-2026 Annual Revenue is Rs 172 Cr which is growth of 184.9% YoY.

  • POSITIVE

    Annual Net Profit Senores Pharmaceuticals Mar-2026 Annual Net Profit is Rs 20 Cr which is growth of 448.8% YoY.

Senores Pharmaceuticals Ltd., Annual, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMMar '26Mar '25Mar '24Mar '23Mar '22Mar '21
107.8%
84.3%
184.5172.460.540.919.216.98.1
Operating Exp. Ann.
106.4%
78.4%
133.9124.845.834.114.214.96.9
Operating Profit Ann.
-
-
-5.7-18.7-7.3-0.1-1.80.91
OPM Ann. %
-
-
 -10.83%-12.03%-0.15%-9.28%5.53%12.58%
⌄
103.5%
79.9%
 14555.438.817.2167.7
EBITDA Ann.
112.1%
108.9%
 47.714.76.8521.2
EBITDA Ann. margin %
1.9%
13.8%
 27.64%24.30%16.61%26.14%11.69%14.46%
Interest Ann.
49.4%
103.6%
8.176.52.72.10.50.2
Depr.
144.8%
85.6%
15.313.23.120.90.60.6
PBT Ann.
143.7%
133.1%
27.327.55.121.90.90.4
Tax Ann.
117.5%
-
7.47.21.41.20.70.6-0.4
156.7%
90.9%
 20.33.70.81.20.30.8
Net Profit Ann.
156.7%
90.9%
19.920.33.70.81.20.30.8
NPM Ann. %
25.4%
12.5%
 19.08%9.57%2.39%9.68%1.84%10.57%
EPS Adj. latest Ann.
144.8%
85.6%
 4.40.80.20.30.10.2
Result Notes
      
Annual Reports
     
*All financials are in INR Cr and price data in INR
Total Rev. Ann.
1Y CHG
185%
2Y CAGR
105.3%
3Y CAGR
107.8%
5Y CAGR
84.3%
Total Revenue Annual growth is higher than historical averages.
Net Profit Ann.
1Y CHG
448.6%
2Y CAGR
403.7%
3Y CAGR
156.7%
5Y CAGR
90.9%
Net Profit Annual growth is higher than historical averages.
Operating Exp. Ann.
1Y CHG
172.5%
2Y CAGR
91.3%
3Y CAGR
106.4%
5Y CAGR
78.4%
Operating Expenses Annual Cr growth is higher than historical averages.

Senores Pharmaceuticals balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history

  • POSITIVE

    Total Shareholders Fund Senores Pharmaceuticals Mar-2026 Total Shareholders Fund is Rs 750 Cr which is growth of 5.9% YoY.

  • POSITIVE

    Total Assets Senores Pharmaceuticals Mar-2026 Total Assets is Rs 888 Cr which is growth of 6.5% YoY.

Senores Pharmaceuticals Ltd., Balance Sheet, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphCAGR 3 YrsCAGR 5 YrsMar '26Mar '25Mar '24Mar '23Mar '22Mar '21
⌄
168.1%
139.6%
749.9708168.138.933.89.5
Minority Interest Liability Ann.
-
-
------
⌄
38.1%
84.5%
68.584.927.1262.23.2
14.1%
97.8%
69.641.290.746.818.82.3
Total Capital Plus Liabilities Ann.
99.6%
126.2%
887.9834.1285.9111.754.715
⌄
79.4%
90.4%
110.288.642.619.14.34.4
⌄
96%
147.6%
632.3422245.98439.56.8
109.7%
99%
255.6412.14027.715.28.2
Total Assets Ann.
99.6%
126.2%
887.9834.1285.9111.754.715
Contingent Liabilities plus Commitments Ann.
-
359.4%
204.717223.30.10.1
Bonus Equity Share Capital Ann.
-
-
Non Current Investments Unquoted Book Value Ann.
166.1%
-
154.5104.481.68.20
Current Investments Unquoted Book Value Ann.
-
-
*All financials are in INR Cr and price data in INR
Total Assets Ann.
1Y CHG
6.5%
2Y CAGR
76.2%
3Y CAGR
99.6%
5Y CAGR
126.2%
Total Assets Annual growth is lower than historical averages.
Total Current Liabilities Ann.
1Y CHG
68.9%
2Y CAGR
-12.4%
3Y CAGR
14.1%
5Y CAGR
97.8%
Total Current Liabilities Annual Cr growth is stable compared to historical averages.
Total ShareHolders Funds Ann.
1Y CHG
5.9%
2Y CAGR
111.2%
3Y CAGR
168.1%
5Y CAGR
139.6%
Total ShareHolders Funds Annual growth is lower than historical averages.

Senores Pharmaceuticals ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history

  • POSITIVE

    Book Value Per Share Senores Pharmaceuticals Mar-2026 Book Value Per Share is 163 Rs which is growth of 5.9% YoY.

  • POSITIVE

    ROE Senores Pharmaceuticals Mar-2026 ROE is 3% which is growth of 2.2% YoY.

Senores Pharmaceuticals Ltd., Ratios, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphCAGR 3 YrsCAGR 5 YrsMar '26Mar '25Mar '24Mar '23Mar '22Mar '21
BVSH Ann.
60.1%
45.6%
162.8153.755.139.738.624.9
RoA Ann. %
28.7%
-16.4%
2.28%0.44%0.28%1.07%0.53%5.58%
ROE Ann. %
-4.3%
-21.1%
2.70%0.52%0.48%3.08%0.86%8.83%
ROCE Ann. %
-12.5%
-2.3%
4.20%1.46%2.43%6.28%3.89%4.73%
⌄
      
⌄
      
⌄
      
Total Debt to Total Equity Ann.
-60.3%
-24.2%
0.10.10.61.60.40.4
*All financials are in INR Cr and price data in INR
ROE Ann. %
1Y CHG
419.2%
2Y CAGR
137.2%
3Y CAGR
-4.3%
5Y CAGR
-21.1%
ROE Annual % is growing faster than historical averages.
RoA Ann. %
1Y CHG
418.2%
2Y CAGR
185.4%
3Y CAGR
28.7%
5Y CAGR
-16.4%
RoA Annual % is growing faster than historical averages.
Current Ratio Ann.
1Y CHG
-63%
2Y CAGR
204.1%
3Y CAGR
83.4%
5Y CAGR
0.5%
Current Ratio Annual is falling faster than historical averages.

Senores Pharmaceuticals cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history

  • NEGATIVE

    Cash From Operating Activity Senores Pharmaceuticals Mar-2026 Cash From Operating Activity is Rs -27 Cr which is growth of -31.8% YoY.

  • NEGATIVE

    Net Cash Flow Senores Pharmaceuticals Mar-2026 Net Cash Flow is Rs -49 Cr which is growth of -114.0% YoY.

Senores Pharmaceuticals Ltd., Cash Flow, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphCAGR 3 YrsCAGR 5 YrsMar '26Mar '25Mar '24Mar '23Mar '22Mar '21
-
-
-26.9-20.4-62.8-43.4-12.2-2.9
Cash from Investing Act. Ann.
-
-
-19.5-162.9-13.5-5.2-11.3-4.4
Cash from Financing Act. Ann.
-
-
-2.6532.686.747.123.48.5
-
-
-49349.310.4-1.6-0.11.3
*All financials are in INR Cr and price data in INR

Senores Pharmaceuticals investor presentations, annual reports, credit ratings, and earnings calls with AI summary, video, and audio access